The global macular degeneration treatment market is poised for significant growth, projected to expand from USD 9.1 billion ...

A study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet age-related macular degeneration ... an experimental drug could be used ...

Age-related macular degeneration is the most common cause of choroidal neovascularization (CNV) and it is an important cause of vision loss in the ageing population. CNV is a multifactorial ...

A new study explains not only why some patients with wet age-related macular degeneration (or 'wet' AMD) fail to have vision improvement with treatment, but also how an experimental drug could be ...

Current treatments sometimes fail to help people with "wet" age-related macular degeneration ... doctors prescribe medications that slow the growth of new blood vessels, called anti-VEGF ...

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...

The US FDA has issued a CRL for sNDA of Astellas Pharma’s IZERVAY, a treatment for geographic atrophy (GA) secondary to AMD.

Astellas Pharma (ALPMY) announced the Food and Drug Administration issued a Complete Response Letter regarding the supplemental new drug ...

"Astellas stands by the clinical profile of Izervay, the only FDA-approved GA treatment that consistently demonstrated ...

The CRL was sent in response to a supplemental New Drug Application for IZERVAY, a treatment for geographic atrophy (GA) ...

Outlook Therapeutics (OTLK) stock plunges 81% after clinical trial failure for its wet AMD therapy, ONS-5010. Read more here.

This rapid growth underscores the increasing demand for advanced biologic therapies to treat retinal disorders, such as ...